#biotech
biotech
229,793 views
411 Discussing
Hot
Latest
·
--
Bullish
$BIO Realiy Check 💋🎀
🧿
Bio Protocol (BIO) has experienced significant attention driven by the intersection of decentralized science (DeSci) and artificial intelligence narratives. Notably, the token recorded heavy trading volumes fueled by high retail demand in Asian markets like South Korea, positioning it among prominent AI-themed digital assets. On the ecosystem front, development has centered on the OpenLabs AI Research Hub—launched to streamline community-driven biotech funding and on-chain governance—alongside foundational V2 upgrades utilizing the BioXP rewards system. Meanwhile, short-term market price action has settled into a consolidation phase around the $0.019 to $0.020 range amid a broader cautious sentiment.
#BioProtocol #Biotech #Reward #Techno
{future}(BIOUSDT)
$BIO Realiy Check 💋🎀
🧿
Bio Protocol (BIO) has experienced significant attention driven by the intersection of decentralized science (DeSci) and artificial intelligence narratives. Notably, the token recorded heavy trading volumes fueled by high retail demand in Asian markets like South Korea, positioning it among prominent AI-themed digital assets. On the ecosystem front, development has centered on the OpenLabs AI Research Hub—launched to streamline community-driven biotech funding and on-chain governance—alongside foundational V2 upgrades utilizing the BioXP rewards system. Meanwhile, short-term market price action has settled into a consolidation phase around the $0.019 to $0.020 range amid a broader cautious sentiment.
#BioProtocol #Biotech #Reward #Techno
🧿
Bio Protocol (BIO) has experienced significant attention driven by the intersection of decentralized science (DeSci) and artificial intelligence narratives. Notably, the token recorded heavy trading volumes fueled by high retail demand in Asian markets like South Korea, positioning it among prominent AI-themed digital assets. On the ecosystem front, development has centered on the OpenLabs AI Research Hub—launched to streamline community-driven biotech funding and on-chain governance—alongside foundational V2 upgrades utilizing the BioXP rewards system. Meanwhile, short-term market price action has settled into a consolidation phase around the $0.019 to $0.020 range amid a broader cautious sentiment.
#BioProtocol #Biotech #Reward #Techno
2
424
·
--
BGI Genomics subsidiary Yongsheng Intelligence signs an agreement with Metware to build China’s first fully automated, end-to-end production line in the field of metabolomics! A powerful partnership in gene sequencing and metabolic mass spectrometry, ushering in a major upgrade in medical technology automation! #HealthTech #Biotech $MTL
BGISEQ's subsidiary Yongsheng Intelligence partners with Metware to build China's first fully automated metabolic production line! Gene sequencing + metabolic mass spectrometry joining forces, medtech automation upgrade! #HealthTech #Biotech $MTL
BGI Genomics subsidiary Yongsheng Intelligence signs an agreement with Metware to build China’s first fully automated, end-to-end production line in the field of metabolomics! A powerful partnership in gene sequencing and metabolic mass spectrometry, ushering in a major upgrade in medical technology automation! #HealthTech #Biotech $MTL
BGISEQ's subsidiary Yongsheng Intelligence partners with Metware to build China's first fully automated metabolic production line! Gene sequencing + metabolic mass spectrometry joining forces, medtech automation upgrade! #HealthTech #Biotech $MTL
BGISEQ's subsidiary Yongsheng Intelligence partners with Metware to build China's first fully automated metabolic production line! Gene sequencing + metabolic mass spectrometry joining forces, medtech automation upgrade! #HealthTech #Biotech $MTL
2
·
--
Amgen stock near $402 before Q3 2026 earnings. The setup: revenue crossed $10B in Q2, guidance raised to $38.2B to $39.4B, and the stock rallied 41% year to date. But management warned operating expenses would rise in the second half.
The risk is margin compression. Q2 non-GAAP margin hit 48%. If Q3 expenses climb as warned while revenue meets rather than beats consensus, margins could dip to the low 40s. For a stock at 25x trailing earnings, that compression matters.
Watching for: revenue above $9.5B, margin above 44%, and Prolia trajectory. Biosimilar pressure took Prolia and XGEVA down 33% in Q2. Not adding before earnings. Your approach may differ.
#AMGN #Amgen #Earnings #Pharma #BioTech
Amgen stock near $402 before Q3 2026 earnings. The setup: revenue crossed $10B in Q2, guidance raised to $38.2B to $39.4B, and the stock rallied 41% year to date. But management warned operating expenses would rise in the second half.
The risk is margin compression. Q2 non-GAAP margin hit 48%. If Q3 expenses climb as warned while revenue meets rather than beats consensus, margins could dip to the low 40s. For a stock at 25x trailing earnings, that compression matters.
Watching for: revenue above $9.5B, margin above 44%, and Prolia trajectory. Biosimilar pressure took Prolia and XGEVA down 33% in Q2. Not adding before earnings. Your approach may differ.
#AMGN #Amgen #Earnings #Pharma #BioTech
The risk is margin compression. Q2 non-GAAP margin hit 48%. If Q3 expenses climb as warned while revenue meets rather than beats consensus, margins could dip to the low 40s. For a stock at 25x trailing earnings, that compression matters.
Watching for: revenue above $9.5B, margin above 44%, and Prolia trajectory. Biosimilar pressure took Prolia and XGEVA down 33% in Q2. Not adding before earnings. Your approach may differ.
#AMGN #Amgen #Earnings #Pharma #BioTech
67
·
--
From code on a screen to the atomic reconstruction of the foundations of life: Why is global pharma’s rush into China’s “AI nanodelivery” considered the most groundbreaking milestone in AI for Science?
For years, many people’s impression of AI drug discovery was still stuck at concept presentations about generating small-molecule compounds. But the real bottleneck in physical drug development isn’t design—it’s “delivery.”
Whether mRNA vaccines or nucleic acid-based gene therapies, 90% are captured and swallowed by the liver after entering the bloodstream, making it virtually impossible to precisely cross the blood-brain barrier or target vital organs such as the lungs and heart. Traditionally, finding effective LNPs (lipid nanoparticles) has relied entirely on chemists screening candidates through trial and error—a process that takes 3–5 years.
Now, generative AI and molecular dynamics modeling have rewritten the rules from the ground up. By reverse-engineering designs from libraries of tens of millions of autonomously generated lipids, they have compressed the development of targeted nanodelivery from years to 2–3 months and enabled tissue-specific delivery to eight major tissue types—prompting multinational giants to commit a staggering $1.1 billion to partnerships.
From computing chips to nanocarriers, technological paradigms are steadily breaking through the physical and biological limits of the real world.
$BTC $BNB #AI #Science #BioTech
From code on a screen to the atomic reconstruction of the foundations of life: Why is global pharma’s rush into China’s “AI nanodelivery” considered the most groundbreaking milestone in AI for Science?
For years, many people’s impression of AI drug discovery was still stuck at concept presentations about generating small-molecule compounds. But the real bottleneck in physical drug development isn’t design—it’s “delivery.”
Whether mRNA vaccines or nucleic acid-based gene therapies, 90% are captured and swallowed by the liver after entering the bloodstream, making it virtually impossible to precisely cross the blood-brain barrier or target vital organs such as the lungs and heart. Traditionally, finding effective LNPs (lipid nanoparticles) has relied entirely on chemists screening candidates through trial and error—a process that takes 3–5 years.
Now, generative AI and molecular dynamics modeling have rewritten the rules from the ground up. By reverse-engineering designs from libraries of tens of millions of autonomously generated lipids, they have compressed the development of targeted nanodelivery from years to 2–3 months and enabled tissue-specific delivery to eight major tissue types—prompting multinational giants to commit a staggering $1.1 billion to partnerships.
From computing chips to nanocarriers, technological paradigms are steadily breaking through the physical and biological limits of the real world.
$BTC $BNB #AI #Science #BioTech
For years, many people’s impression of AI drug discovery was still stuck at concept presentations about generating small-molecule compounds. But the real bottleneck in physical drug development isn’t design—it’s “delivery.”
Whether mRNA vaccines or nucleic acid-based gene therapies, 90% are captured and swallowed by the liver after entering the bloodstream, making it virtually impossible to precisely cross the blood-brain barrier or target vital organs such as the lungs and heart. Traditionally, finding effective LNPs (lipid nanoparticles) has relied entirely on chemists screening candidates through trial and error—a process that takes 3–5 years.
Now, generative AI and molecular dynamics modeling have rewritten the rules from the ground up. By reverse-engineering designs from libraries of tens of millions of autonomously generated lipids, they have compressed the development of targeted nanodelivery from years to 2–3 months and enabled tissue-specific delivery to eight major tissue types—prompting multinational giants to commit a staggering $1.1 billion to partnerships.
From computing chips to nanocarriers, technological paradigms are steadily breaking through the physical and biological limits of the real world.
$BTC $BNB #AI #Science #BioTech
231
·
--
Nearshore Protein's AI business has just gotten off the ground, contributing less than 2% of revenue! The company warns: although AI drug development is a hot trend, technology is evolving rapidly, validation cycles are long, and commercialization is challenging. Future revenue is highly uncertain. Invest with caution! #AI #生物科技 $RNDR
Jinyan Protein's AI business is just starting, contributing less than 2% to revenue! The company warns: while AI drug development is trending, it faces rapid tech changes, long validation cycles, and commercialization challenges. Future revenue remains uncertain. Invest with caution! #AI #Biotech $RNDR
Nearshore Protein's AI business has just gotten off the ground, contributing less than 2% of revenue! The company warns: although AI drug development is a hot trend, technology is evolving rapidly, validation cycles are long, and commercialization is challenging. Future revenue is highly uncertain. Invest with caution! #AI #生物科技 $RNDR
Jinyan Protein's AI business is just starting, contributing less than 2% to revenue! The company warns: while AI drug development is trending, it faces rapid tech changes, long validation cycles, and commercialization challenges. Future revenue remains uncertain. Invest with caution! #AI #Biotech $RNDR
Jinyan Protein's AI business is just starting, contributing less than 2% to revenue! The company warns: while AI drug development is trending, it faces rapid tech changes, long validation cycles, and commercialization challenges. Future revenue remains uncertain. Invest with caution! #AI #Biotech $RNDR
10
·
--
Genmab surges nearly 30% to a record high: Tonight’s biotech breakout in U.S. stocks is here
The epicenter of tonight’s biotech storm in the U.S. stock market is Danish antibody giant Genmab ($GMAB).
The stock surged nearly 30% intraday (+28.3%), soaring to a record high. Goldman Sachs and other major investment banks swiftly raised their price targets.
[Key catalysts]
1. Breakthrough cancer trial data: In a pivotal late-stage clinical trial, an experimental treatment for advanced cancer developed by Genmab directly cut patients’ risk of death by 50%—a major game-changing breakthrough in oncology.
2. Double earnings beat: Quarterly results released the same day topped expectations across the board (Q3 EPS of $0.54, well above the $0.37 forecast, with revenue of $1.16 billion).
3. Sector-wide momentum: Following a wave of ADC and bispecific antibody data releases at the ESMO Congress, Genmab’s major results have sparked a global reassessment of innovative antibody pipelines. Biotech stocks such as Moderna and Alnylam are also climbing across the board in premarket trading.
When a cancer drug cuts the death rate in half in a late-stage trial, it can trigger a commercial revaluation worth tens of billions of dollars.
Do you think this biotech rally marks a genuine breakout, or is it just a news-driven spike? Are you taking profits tonight or holding on to your biotech stocks?
$BTC $ETH #Biotech #Genmab #Binance Square
Genmab surges nearly 30% to a record high: Tonight’s biotech breakout in U.S. stocks is here
The epicenter of tonight’s biotech storm in the U.S. stock market is Danish antibody giant Genmab ($GMAB).
The stock surged nearly 30% intraday (+28.3%), soaring to a record high. Goldman Sachs and other major investment banks swiftly raised their price targets.
[Key catalysts]
1. Breakthrough cancer trial data: In a pivotal late-stage clinical trial, an experimental treatment for advanced cancer developed by Genmab directly cut patients’ risk of death by 50%—a major game-changing breakthrough in oncology.
2. Double earnings beat: Quarterly results released the same day topped expectations across the board (Q3 EPS of $0.54, well above the $0.37 forecast, with revenue of $1.16 billion).
3. Sector-wide momentum: Following a wave of ADC and bispecific antibody data releases at the ESMO Congress, Genmab’s major results have sparked a global reassessment of innovative antibody pipelines. Biotech stocks such as Moderna and Alnylam are also climbing across the board in premarket trading.
When a cancer drug cuts the death rate in half in a late-stage trial, it can trigger a commercial revaluation worth tens of billions of dollars.
Do you think this biotech rally marks a genuine breakout, or is it just a news-driven spike? Are you taking profits tonight or holding on to your biotech stocks?
$BTC $ETH #Biotech #Genmab #Binance Square
The epicenter of tonight’s biotech storm in the U.S. stock market is Danish antibody giant Genmab ($GMAB).
The stock surged nearly 30% intraday (+28.3%), soaring to a record high. Goldman Sachs and other major investment banks swiftly raised their price targets.
[Key catalysts]
1. Breakthrough cancer trial data: In a pivotal late-stage clinical trial, an experimental treatment for advanced cancer developed by Genmab directly cut patients’ risk of death by 50%—a major game-changing breakthrough in oncology.
2. Double earnings beat: Quarterly results released the same day topped expectations across the board (Q3 EPS of $0.54, well above the $0.37 forecast, with revenue of $1.16 billion).
3. Sector-wide momentum: Following a wave of ADC and bispecific antibody data releases at the ESMO Congress, Genmab’s major results have sparked a global reassessment of innovative antibody pipelines. Biotech stocks such as Moderna and Alnylam are also climbing across the board in premarket trading.
When a cancer drug cuts the death rate in half in a late-stage trial, it can trigger a commercial revaluation worth tens of billions of dollars.
Do you think this biotech rally marks a genuine breakout, or is it just a news-driven spike? Are you taking profits tonight or holding on to your biotech stocks?
$BTC $ETH #Biotech #Genmab #Binance Square
GMABUS-0.19%
12
🚀 $MRNA REBOUND AFTER AI‑POWERED CANCER VACCINE DATA! 📈
Entry: 202.63 ⚡
The 17.5% drop to $202.63 was a textbook sell‑the‑news dump, but the price floor at $180.80 held firm, suggesting liquidity was soaked up by smart‑money sharks. 📊 Volume surged as buyers reclaimed the level, turning the dip into a potential springboard. ⚡
Now the Phase 3 INTerpath‑001 readout shows a 42% cut in recurrence risk when paired with Keytruda, and AI giants like OpenAI are locking in biotech partnerships. 🦈 This convergence of clinical data and AI could fuel a fresh upside wave. 💡
💬 Are you loading up on $MRNA or waiting for the next AI catalyst? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #MRNA #AI #Biotech #Breakout
🔥 💎
🚀 $MRNA REBOUND AFTER AI‑POWERED CANCER VACCINE DATA! 📈
Entry: 202.63 ⚡
The 17.5% drop to $202.63 was a textbook sell‑the‑news dump, but the price floor at $180.80 held firm, suggesting liquidity was soaked up by smart‑money sharks. 📊 Volume surged as buyers reclaimed the level, turning the dip into a potential springboard. ⚡
Now the Phase 3 INTerpath‑001 readout shows a 42% cut in recurrence risk when paired with Keytruda, and AI giants like OpenAI are locking in biotech partnerships. 🦈 This convergence of clinical data and AI could fuel a fresh upside wave. 💡
💬 Are you loading up on $MRNA or waiting for the next AI catalyst? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #MRNA #AI #Biotech #Breakout
🔥 💎
Entry: 202.63 ⚡
The 17.5% drop to $202.63 was a textbook sell‑the‑news dump, but the price floor at $180.80 held firm, suggesting liquidity was soaked up by smart‑money sharks. 📊 Volume surged as buyers reclaimed the level, turning the dip into a potential springboard. ⚡
Now the Phase 3 INTerpath‑001 readout shows a 42% cut in recurrence risk when paired with Keytruda, and AI giants like OpenAI are locking in biotech partnerships. 🦈 This convergence of clinical data and AI could fuel a fresh upside wave. 💡
💬 Are you loading up on $MRNA or waiting for the next AI catalyst? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #MRNA #AI #Biotech #Breakout
🔥 💎
23
·
--
Bullish
🚨🦟 $GOOGL -BACKED MOSQUITO RELEASE? THE INTERNET IS PANICKING... BUT HERE'S WHAT THEY'RE NOT TELLING YOU 👀👇
32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸
Sounds terrifying, right? 😳
{future}(GOOGLUSDT)
But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇
🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases.
The mission? 🎯
✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides
Here's where things get interesting... 👀
❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES.
And male mosquitoes don't bite humans. 🦟🚫
Instead, they carry a naturally occurring bacterium called Wolbachia.
When they mate with wild female mosquitoes:
📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time
💡 Why are scientists exploring this?
Because some mosquito species are becoming increasingly resistant to traditional pesticides.
Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎
🤔 The bigger question:
If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases...
Would YOU support releasing millions of non-biting mosquitoes? 👇
🔥 YES — if it saves lives 😬 NO — too many unknown risks
Drop your answer below and let's discuss! 💬
$STRAX
{spot}(STRAXUSDT)
#Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder
📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)
🚨🦟 $GOOGL -BACKED MOSQUITO RELEASE? THE INTERNET IS PANICKING... BUT HERE'S WHAT THEY'RE NOT TELLING YOU 👀👇
32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸
Sounds terrifying, right? 😳
But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇
🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases.
The mission? 🎯
✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides
Here's where things get interesting... 👀
❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES.
And male mosquitoes don't bite humans. 🦟🚫
Instead, they carry a naturally occurring bacterium called Wolbachia.
When they mate with wild female mosquitoes:
📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time
💡 Why are scientists exploring this?
Because some mosquito species are becoming increasingly resistant to traditional pesticides.
Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎
🤔 The bigger question:
If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases...
Would YOU support releasing millions of non-biting mosquitoes? 👇
🔥 YES — if it saves lives 😬 NO — too many unknown risks
Drop your answer below and let's discuss! 💬
$STRAX
#Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder
📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)
32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸
Sounds terrifying, right? 😳
But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇
🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases.
The mission? 🎯
✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides
Here's where things get interesting... 👀
❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES.
And male mosquitoes don't bite humans. 🦟🚫
Instead, they carry a naturally occurring bacterium called Wolbachia.
When they mate with wild female mosquitoes:
📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time
💡 Why are scientists exploring this?
Because some mosquito species are becoming increasingly resistant to traditional pesticides.
Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎
🤔 The bigger question:
If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases...
Would YOU support releasing millions of non-biting mosquitoes? 👇
🔥 YES — if it saves lives 😬 NO — too many unknown risks
Drop your answer below and let's discuss! 💬
$STRAX
#Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder
📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)
3
149
·
--
$BIO
{future}(BIOUSDT)
BIO is doing exactly what a healthy trend does – keeping buying activity right near the support level. Each dip is defended faster than the previous one, and the structure has never been broken. Volume is increasing imperceptibly.
A break could open the way for an upside move, and the risk-reward ratio is clean from here.
Do you support the bid or wait for a breakout?
#BIO #BİO #Biotech
$BIO
BIO is doing exactly what a healthy trend does – keeping buying activity right near the support level. Each dip is defended faster than the previous one, and the structure has never been broken. Volume is increasing imperceptibly.
A break could open the way for an upside move, and the risk-reward ratio is clean from here.
Do you support the bid or wait for a breakout?
#BIO #BİO #Biotech
BIO is doing exactly what a healthy trend does – keeping buying activity right near the support level. Each dip is defended faster than the previous one, and the structure has never been broken. Volume is increasing imperceptibly.
A break could open the way for an upside move, and the risk-reward ratio is clean from here.
Do you support the bid or wait for a breakout?
#BIO #BİO #Biotech
105
·
--
$BIO
{future}(BIOUSDT)
The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers.
#BİO #Biotech #TradingTales
$BIO
The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers.
#BİO #Biotech #TradingTales
The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers.
#BİO #Biotech #TradingTales
386
·
--
Article
STOCKS | iShares Biotechnology ETF Rises 3.2%, State Street SPDR S&P Biotechnology ETF Gains 2.9%The iShares Biotechnology ETF experienced a notable rise of 3.2% in the market, according to Jin10, reflecting renewed investor interest in the biotech sector. On the same day, the State Street SPDR S&P Biotechnology ETF also gained 2.9%, indicating broad-based positive sentiment among biotech-focused funds.
This rally suggests that investors are increasingly optimistic about the prospects of biotech companies, possibly driven by recent advancements, regulatory developments, or favorable earnings reports within the industry. The gains across these ETFs highlight a shift in market sentiment towards risk-on behavior in the healthcare and biotech sectors.
The biotech ETFs' positive movement also underscores ongoing interest from institutional investors in healthcare innovation and emerging biotech firms. These funds often serve as barometers for broader industry confidence, and their gains may signal an upcoming period of increased activity and investment in biotech equities.
Overall, the rise in both ETFs points to a potential rebound or sustained optimism in the biotech sector, which has faced volatility in recent months. Market participants will likely continue to monitor developments in biotechnology for clues on future investment trends. #Biotech #ETFs #MarketUpdate
STOCKS | iShares Biotechnology ETF Rises 3.2%, State Street SPDR S&P Biotechnology ETF Gains 2.9%
The iShares Biotechnology ETF experienced a notable rise of 3.2% in the market, according to Jin10, reflecting renewed investor interest in the biotech sector. On the same day, the State Street SPDR S&P Biotechnology ETF also gained 2.9%, indicating broad-based positive sentiment among biotech-focused funds.
This rally suggests that investors are increasingly optimistic about the prospects of biotech companies, possibly driven by recent advancements, regulatory developments, or favorable earnings reports within the industry. The gains across these ETFs highlight a shift in market sentiment towards risk-on behavior in the healthcare and biotech sectors.
The biotech ETFs' positive movement also underscores ongoing interest from institutional investors in healthcare innovation and emerging biotech firms. These funds often serve as barometers for broader industry confidence, and their gains may signal an upcoming period of increased activity and investment in biotech equities.
Overall, the rise in both ETFs points to a potential rebound or sustained optimism in the biotech sector, which has faced volatility in recent months. Market participants will likely continue to monitor developments in biotechnology for clues on future investment trends. #Biotech #ETFs #MarketUpdate
This rally suggests that investors are increasingly optimistic about the prospects of biotech companies, possibly driven by recent advancements, regulatory developments, or favorable earnings reports within the industry. The gains across these ETFs highlight a shift in market sentiment towards risk-on behavior in the healthcare and biotech sectors.
The biotech ETFs' positive movement also underscores ongoing interest from institutional investors in healthcare innovation and emerging biotech firms. These funds often serve as barometers for broader industry confidence, and their gains may signal an upcoming period of increased activity and investment in biotech equities.
Overall, the rise in both ETFs points to a potential rebound or sustained optimism in the biotech sector, which has faced volatility in recent months. Market participants will likely continue to monitor developments in biotechnology for clues on future investment trends. #Biotech #ETFs #MarketUpdate
56
·
--
Bullish
🚨 $MRNA
{future}(MRNAUSDT)
— CANCER VACCINE MILESTONE
$MRNA has more than doubled since mid-August, fueled by the Moderna–Merck cancer vaccine Phase 3 success.
🔥 This marks a major milestone: the first Phase 3 efficacy readout for a therapeutic cancer vaccine.
📈 The move highlights how powerful clinical breakthroughs can be for biotech valuations.
👀 $MRNA remains one to watch as the market continues to price in the potential impact of this breakthrough.
#MRNA #Biotech #CancerVaccine #StocksToBinance
🚨 $MRNA
— CANCER VACCINE MILESTONE
$MRNA has more than doubled since mid-August, fueled by the Moderna–Merck cancer vaccine Phase 3 success.
🔥 This marks a major milestone: the first Phase 3 efficacy readout for a therapeutic cancer vaccine.
📈 The move highlights how powerful clinical breakthroughs can be for biotech valuations.
👀 $MRNA remains one to watch as the market continues to price in the potential impact of this breakthrough.
#MRNA #Biotech #CancerVaccine #StocksToBinance
— CANCER VACCINE MILESTONE
$MRNA has more than doubled since mid-August, fueled by the Moderna–Merck cancer vaccine Phase 3 success.
🔥 This marks a major milestone: the first Phase 3 efficacy readout for a therapeutic cancer vaccine.
📈 The move highlights how powerful clinical breakthroughs can be for biotech valuations.
👀 $MRNA remains one to watch as the market continues to price in the potential impact of this breakthrough.
#MRNA #Biotech #CancerVaccine #StocksToBinance
126
·
--
Bullish
Moderna and Merck’s mRNA cancer vaccine meets Phase 3 endpoints, sending Moderna shares sharply higher
🧬 Moderna and Merck said their personalized mRNA vaccine, intismeran autogene, combined with Keytruda met both the primary recurrence-free survival endpoint and the key secondary distant metastasis-free survival endpoint in the Phase 3 INTerpath-001 trial involving 1,137 patients with surgically resected melanoma.
📈 The result marks the first Phase 3 success for an mRNA-based cancer therapy and an individualized neoantigen vaccine, reinforcing the positive signal previously seen in the Phase 2b study.
💹 Market reaction was strong, with Moderna shares rising around 90–100%+ in premarket trading, while Merck gained roughly 6–9%.
⚠️ However, detailed data such as the hazard ratio and absolute benefit have not yet been released, while overall survival remains under follow-up. The longer-term impact will depend on the full dataset and regulatory progress.
#Biotech $MRNAon $MRK.US $BNB
Moderna and Merck’s mRNA cancer vaccine meets Phase 3 endpoints, sending Moderna shares sharply higher
🧬 Moderna and Merck said their personalized mRNA vaccine, intismeran autogene, combined with Keytruda met both the primary recurrence-free survival endpoint and the key secondary distant metastasis-free survival endpoint in the Phase 3 INTerpath-001 trial involving 1,137 patients with surgically resected melanoma.
📈 The result marks the first Phase 3 success for an mRNA-based cancer therapy and an individualized neoantigen vaccine, reinforcing the positive signal previously seen in the Phase 2b study.
💹 Market reaction was strong, with Moderna shares rising around 90–100%+ in premarket trading, while Merck gained roughly 6–9%.
⚠️ However, detailed data such as the hazard ratio and absolute benefit have not yet been released, while overall survival remains under follow-up. The longer-term impact will depend on the full dataset and regulatory progress.
#Biotech $MRNAon $MRK.US $BNB
🧬 Moderna and Merck said their personalized mRNA vaccine, intismeran autogene, combined with Keytruda met both the primary recurrence-free survival endpoint and the key secondary distant metastasis-free survival endpoint in the Phase 3 INTerpath-001 trial involving 1,137 patients with surgically resected melanoma.
📈 The result marks the first Phase 3 success for an mRNA-based cancer therapy and an individualized neoantigen vaccine, reinforcing the positive signal previously seen in the Phase 2b study.
💹 Market reaction was strong, with Moderna shares rising around 90–100%+ in premarket trading, while Merck gained roughly 6–9%.
⚠️ However, detailed data such as the hazard ratio and absolute benefit have not yet been released, while overall survival remains under follow-up. The longer-term impact will depend on the full dataset and regulatory progress.
#Biotech $MRNAon $MRK.US $BNB
MRNAonAlpha
MRKUS-0.11%
449
·
--
The biggest wealth transfer in crypto won't come from finance. It will come from biology.
Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here.
The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors.
Blockchain infrastructure is completely restructuring this system.
Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments.
If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress.
The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet.
$NMR $RIF $BIO
#Write2Earn #DeSci #Biotech #CryptoTrends
The biggest wealth transfer in crypto won't come from finance. It will come from biology.
Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here.
The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors.
Blockchain infrastructure is completely restructuring this system.
Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments.
If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress.
The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet.
$NMR $RIF $BIO
#Write2Earn #DeSci #Biotech #CryptoTrends
Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here.
The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors.
Blockchain infrastructure is completely restructuring this system.
Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments.
If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress.
The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet.
$NMR $RIF $BIO
#Write2Earn #DeSci #Biotech #CryptoTrends
295
·
--
Good news for glioma patients! Haisco's innovative drug has been recognized for breakthrough treatment and is on the fast track to approval! 🚀🧠 Combining pharma innovation with blockchain is the way forward—medical tokens like $MED are worth keeping an eye on! #生物科技 #DeFi
Brain tumor treatment breakthrough! Haisco's drug gets fast-track approval. 🚀🧠 Pharma innovation + blockchain = future goldmine. Keep an eye on $MED! #Biotech #DeFi
Good news for glioma patients! Haisco's innovative drug has been recognized for breakthrough treatment and is on the fast track to approval! 🚀🧠 Combining pharma innovation with blockchain is the way forward—medical tokens like $MED are worth keeping an eye on! #生物科技 #DeFi
Brain tumor treatment breakthrough! Haisco's drug gets fast-track approval. 🚀🧠 Pharma innovation + blockchain = future goldmine. Keep an eye on $MED! #Biotech #DeFi
Brain tumor treatment breakthrough! Haisco's drug gets fast-track approval. 🚀🧠 Pharma innovation + blockchain = future goldmine. Keep an eye on $MED! #Biotech #DeFi
20
·
--
逢时科技启动上市辅导啦！这家做南极磷虾生物制品的创新企业要登陆资本市场了，海洋科技领域又添新力量！#生物科技 #海洋科技 $OCEAN
Fengshi Tech just kicked off IPO prep! This innovative company focusing on Antarctic krill biotech products is heading to the capital markets. Ocean tech sector just got stronger! #Biotech #MarineTech $OCEAN
逢时科技启动上市辅导啦！这家做南极磷虾生物制品的创新企业要登陆资本市场了，海洋科技领域又添新力量！#生物科技 #海洋科技 $OCEAN
Fengshi Tech just kicked off IPO prep! This innovative company focusing on Antarctic krill biotech products is heading to the capital markets. Ocean tech sector just got stronger! #Biotech #MarineTech $OCEAN
Fengshi Tech just kicked off IPO prep! This innovative company focusing on Antarctic krill biotech products is heading to the capital markets. Ocean tech sector just got stronger! #Biotech #MarineTech $OCEAN
22
·
--
📈 #ModernaRisesOver12% — Biotech Giant Surges on New Pipeline Data
Moderna shares jumping over 12% after positive clinical trial data for its next-generation mRNA vaccine pipeline. Investors piling back into biotech as Moderna demonstrates progress beyond COVID-19 vaccines.
#ModernaRisesOver12% #Biotech #MRNA
📈 #ModernaRisesOver12% — Biotech Giant Surges on New Pipeline Data
Moderna shares jumping over 12% after positive clinical trial data for its next-generation mRNA vaccine pipeline. Investors piling back into biotech as Moderna demonstrates progress beyond COVID-19 vaccines.
#ModernaRisesOver12% #Biotech #MRNA
Moderna shares jumping over 12% after positive clinical trial data for its next-generation mRNA vaccine pipeline. Investors piling back into biotech as Moderna demonstrates progress beyond COVID-19 vaccines.
#ModernaRisesOver12% #Biotech #MRNA
MRNAonAlpha
MRNAUS+0.88%
82
·
--
🚨 $XBI
{future}(XBIUSDT)
USDT Perp is almost live on Binance Futures 🚨
Another fresh listing is about to hit the board — XBIUSDT Perpetual is counting down and the market is getting ready. 👀🔥
Pair: XBIUSDT Perp
Underlying asset: SPDR S&P Biotech ETF (XBI)
Platform: Binance Futures
Status: Pre-launch / trading not open yet
Countdown shown: 01 Hour 25 Min 44 Sec remaining at the time of screenshot
Right now, price and market stats are still inactive:
Last Price: 0.00
Mark Price: 0.00
24h High / Low: 0.00 / 0.00
24h Volume: 0.00
That usually means the contract page is live before actual trading starts, giving traders time to prepare for the opening volatility. Since XBI tracks the biotech sector, this launch is interesting because it brings a traditional biotech ETF exposure into perpetual futures trading format.
What to watch at open:
First few candles for volatility spike
Funding and liquidity behavior
Early long/short battle after listing goes live
Binance is opening the door for biotech-linked perp action — XBIUSDT could get very wild right after launch. 📈⚡
#Binance #Futures #XBIUSDT #Perpetual #CryptoTrading #Biotech
ParadigmRaises$1.2BThirdFundForAIAndRobotics
#FedMinutesShowSplitOnRateHikes
#SonyGetsOCCApprovalForStablecoinTrust
#KOSPIJumpsNearly4%To7539
#SKHynixUSListingOversubscribed7x
🚨 $XBI
USDT Perp is almost live on Binance Futures 🚨
Another fresh listing is about to hit the board — XBIUSDT Perpetual is counting down and the market is getting ready. 👀🔥
Pair: XBIUSDT Perp
Underlying asset: SPDR S&P Biotech ETF (XBI)
Platform: Binance Futures
Status: Pre-launch / trading not open yet
Countdown shown: 01 Hour 25 Min 44 Sec remaining at the time of screenshot
Right now, price and market stats are still inactive:
Last Price: 0.00
Mark Price: 0.00
24h High / Low: 0.00 / 0.00
24h Volume: 0.00
That usually means the contract page is live before actual trading starts, giving traders time to prepare for the opening volatility. Since XBI tracks the biotech sector, this launch is interesting because it brings a traditional biotech ETF exposure into perpetual futures trading format.
What to watch at open:
First few candles for volatility spike
Funding and liquidity behavior
Early long/short battle after listing goes live
Binance is opening the door for biotech-linked perp action — XBIUSDT could get very wild right after launch. 📈⚡
#Binance #Futures #XBIUSDT #Perpetual #CryptoTrading #Biotech
ParadigmRaises$1.2BThirdFundForAIAndRobotics
#FedMinutesShowSplitOnRateHikes
#SonyGetsOCCApprovalForStablecoinTrust
#KOSPIJumpsNearly4%To7539
#SKHynixUSListingOversubscribed7x
USDT Perp is almost live on Binance Futures 🚨
Another fresh listing is about to hit the board — XBIUSDT Perpetual is counting down and the market is getting ready. 👀🔥
Pair: XBIUSDT Perp
Underlying asset: SPDR S&P Biotech ETF (XBI)
Platform: Binance Futures
Status: Pre-launch / trading not open yet
Countdown shown: 01 Hour 25 Min 44 Sec remaining at the time of screenshot
Right now, price and market stats are still inactive:
Last Price: 0.00
Mark Price: 0.00
24h High / Low: 0.00 / 0.00
24h Volume: 0.00
That usually means the contract page is live before actual trading starts, giving traders time to prepare for the opening volatility. Since XBI tracks the biotech sector, this launch is interesting because it brings a traditional biotech ETF exposure into perpetual futures trading format.
What to watch at open:
First few candles for volatility spike
Funding and liquidity behavior
Early long/short battle after listing goes live
Binance is opening the door for biotech-linked perp action — XBIUSDT could get very wild right after launch. 📈⚡
#Binance #Futures #XBIUSDT #Perpetual #CryptoTrading #Biotech
ParadigmRaises$1.2BThirdFundForAIAndRobotics
#FedMinutesShowSplitOnRateHikes
#SonyGetsOCCApprovalForStablecoinTrust
#KOSPIJumpsNearly4%To7539
#SKHynixUSListingOversubscribed7x
1
235
🍄 Peter Brandt talks about “magic mushrooms.” What if real mushrooms are already becoming technology?
In crypto, 🍄 is a metaphor for self-deception: when an investor sees only $1 million per BTC and stops noticing the risks.
But in the real world, mushrooms are already biotechnology, new materials, and AI.
Mushrooms Inc. (OTC: MSRM) announced a Proof of Concept for MycoLabX: mycelium films demonstrated a color change when interacting with bacteria. Potential applications include technologies for the early detection of infections, particularly in wound care.
At the same time, the company is developing MycoLab.ai — an AI platform for working with scientific data on mycology.
But DVA reminds you:
Proof of Concept ≠ finished product.
Technology ≠ commercial success.
OTC stock ≠ guaranteed profit.
MSRM is a very small, high-risk company. So we’re watching the facts, not the attractive story: independent validation, partners, funding, and actual commercialization.
🍄 Mushrooms can be technology.
But investors shouldn’t turn into mushrooms themselves.
DVA — facts without hype.
Not financial advice.
Preserving value and time.
#DVA #Biotech #AI #Mycelium #MSRM
🍄 Peter Brandt talks about “magic mushrooms.” What if real mushrooms are already becoming technology?
In crypto, 🍄 is a metaphor for self-deception: when an investor sees only $1 million per BTC and stops noticing the risks.
But in the real world, mushrooms are already biotechnology, new materials, and AI.
Mushrooms Inc. (OTC: MSRM) announced a Proof of Concept for MycoLabX: mycelium films demonstrated a color change when interacting with bacteria. Potential applications include technologies for the early detection of infections, particularly in wound care.
At the same time, the company is developing MycoLab.ai — an AI platform for working with scientific data on mycology.
But DVA reminds you:
Proof of Concept ≠ finished product.
Technology ≠ commercial success.
OTC stock ≠ guaranteed profit.
MSRM is a very small, high-risk company. So we’re watching the facts, not the attractive story: independent validation, partners, funding, and actual commercialization.
🍄 Mushrooms can be technology.
But investors shouldn’t turn into mushrooms themselves.
DVA — facts without hype.
Not financial advice.
Preserving value and time.
#DVA #Biotech #AI #Mycelium #MSRM
In crypto, 🍄 is a metaphor for self-deception: when an investor sees only $1 million per BTC and stops noticing the risks.
But in the real world, mushrooms are already biotechnology, new materials, and AI.
Mushrooms Inc. (OTC: MSRM) announced a Proof of Concept for MycoLabX: mycelium films demonstrated a color change when interacting with bacteria. Potential applications include technologies for the early detection of infections, particularly in wound care.
At the same time, the company is developing MycoLab.ai — an AI platform for working with scientific data on mycology.
But DVA reminds you:
Proof of Concept ≠ finished product.
Technology ≠ commercial success.
OTC stock ≠ guaranteed profit.
MSRM is a very small, high-risk company. So we’re watching the facts, not the attractive story: independent validation, partners, funding, and actual commercialization.
🍄 Mushrooms can be technology.
But investors shouldn’t turn into mushrooms themselves.
DVA — facts without hype.
Not financial advice.
Preserving value and time.
#DVA #Biotech #AI #Mycelium #MSRM
2
369
·
--
$BIO
{future}(BIOUSDT)
Trading volumes remain stable, without sharp sales spikes. The structure indicates the formation of higher lows and higher highs. Buyers are actively defending the entry zones, not allowing prices to fall. In the event of a resistance breakdown, the momentum can accelerate significantly.
#BIO #BİO #Biotech
$BIO
Trading volumes remain stable, without sharp sales spikes. The structure indicates the formation of higher lows and higher highs. Buyers are actively defending the entry zones, not allowing prices to fall. In the event of a resistance breakdown, the momentum can accelerate significantly.
#BIO #BİO #Biotech
Trading volumes remain stable, without sharp sales spikes. The structure indicates the formation of higher lows and higher highs. Buyers are actively defending the entry zones, not allowing prices to fall. In the event of a resistance breakdown, the momentum can accelerate significantly.
#BIO #BİO #Biotech
103
Log in to explore more content
Join global crypto users on Binance Square
⚡️ Get latest and useful information about crypto.
💬 Trusted by the world’s largest crypto exchange.
👍 Discover real insights from verified creators.
Email / Phone number
Trending Topics
1
#CPITestsDecemberRateOutlook
729,171 views
3,485 Discussing
2
#NvidiaInvestigatesAfterHuang’sAffairApology
286,304 views
2,238 Discussing
3
#AnthropicRejectsIPODelayValuationinQuestion
75,727 views
712 Discussing
4
#US-IranTalksFuelStrongStockMarketRebound
18,532 views
220 Discussing
5
#BitcoinFiveWeeklyLosses
310,611 views
2,562 Discussing
6
#AIChipSlumpNasdaq
176,038 views
1,551 Discussing
7
#BitcoinSpotETFsPost$201MNetOutflowForThirdStraightDay
180 views
3 Discussing
8
#CryptoLiquidationsReach$1.16BIn24Hours
30,672 views
63 Discussing
9
#TetherFreezes5EthereumAddressesHoldingAbout24.35MUSDT
47 views
2 Discussing
10
#StrategyBuys1037BTCLastWeek
8,661 views
108 Discussing